FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer. METHODS: We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis], leucovorin [400 mg per square meter], and fluorouracil [2400 mg per square meter] every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety. RESULTS: At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.73; P<0.001). The disease-free survival rate at 3 years was 39.7% in the modified-FOLFIRINOX group and 21.4% in the gemcitabine group. The median overall survival was 54.4 months in the modified-FOLFIRINOX group and 35.0 months in the gemcitabine group (stratified hazard ratio for death, 0.64; 95% CI, 0.48 to 0.86; P=0.003). The overall survival rate at 3 years was 63.4% in the modified-FOLFIRINOX group and 48.6% in the gemcitabine group. Adverse events of grade 3 or 4 occurred in 75.9% of the patients in the modified-FOLFIRINOX group and in 52.9% of those in the gemcitabine group. One patient in the gemcitabine group died from toxic effects (interstitial pneumonitis). CONCLUSIONS: Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135 ; EudraCT number, 2011-002026-52 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Polychemotherapy, either with 5-fluorouracil (5-FU), irinotecan and oxaliplatin in combination with folinic acid (FOLFIRINOX), or with gemcitabine and nab-paclitaxel (GnP), is considered the standard of care for patients suffering from metastatic PDAC (mPDAC)3,4.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
In the citing paper
“Less than half of all patients respond to the primary treatment for PDAC, chemotherapy3,4”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationRahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32409-6 · Cited by 1,926
Self-citationOettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Research works printed but not linked: 1
- Early Breast Cancer Trialists’ Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford England: Oxford University Press 1990.
Cited by
Items 601–700 of 1,002
Belfiori, G., Fiorentini, G., Tamburrino, D., Partelli, S., Pagnanelli, M., Gasparini, G., Castoldi, R., Balzano, G., Rubini, C., Zamboni, G., et al. (2020) · Surgery · doi:10.1016/j.surg.2020.08.002 · Cited by 26
Voss, N., Izbicki, J. R., & Nentwich, M. F. (2019) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12255 · Cited by 24
Zhao, B., Qin, C., Li, Z., Wang, Y., Li, T., Cao, H., Yang, X., Li, T., & Wang, W. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02785-7 · Cited by 27
the Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators, Barbour, A. P., Samra, J. S., Haghighi, K. S., Donoghoe, M. W., Burge, M., Harris, M., Chua, Y. J., Mitchell, J., O’Rourke, N., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08205-2 · Cited by 23
Satoi, S., Yamamoto, T., Uchida, K., Fujii, T., Kin, T., Hirano, S., Hanada, K., Itoi, T., Murakami, Y., Igarashi, H., et al. (2020) · Pancreas · doi:10.1097/mpa.0000000000001579 · Cited by 23
Chopra, A., Hodges, J. C., Olson, A. C., Burton, S. A., Ellsworth, S. G., Bahary, N., Singhi, A. D., Boone, B. A., Beane, J. D., Bartlett, D. L., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09391-9 · Cited by 22
Krell, R. W., McNeil, L. R., Yanala, U., Are, C., & Reames, B. N. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09460-z · Cited by 25
Guidelines for the diagnosis and treatment of pancreatic cancer in China (2021)
Yang, Y., Bai, X., Bian, D., Cai, S., Chen, R., Cao, F., Dai, M., Fang, C., Fu, D., Ge, C., et al. (2021) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000072 · Cited by 24
Wang, Y., Golesworthy, B., Cuggia, A., Domecq, C., Chaudhury, P. K., Barkun, J. S., Metrakos, P. P., Asselah, J., Bouganim, N., Gao, Z., et al. (2021) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2021-108054 · Cited by 26
Schlick, K., Kiem, D., & Greil, R. (2021) · Biomolecules · doi:10.3390/biom11101469 · Cited by 24
Su, Y., Chiu, Y., Li, C., Yang, S., Lin, J., Lin, S., Chang, P., Chiang, N., Shan, Y., Ch’ang, H.-J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01649-7 · Cited by 23
“4% in an adjuvant trial for resectable pancreatic cancer [25].”
BackgroundPietrasz, D., Sereni, E., Lancellotti, F., Pea, A., Luchini, C., Innamorati, G., Salvia, R., & Bassi, C. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01745-2 · Cited by 28
“However, survival remains disappointing with a median 5-year survival of only 20–30% in resected patients and 3-year relapse-free survival (RFS) inferior to 40% in resected PDAC treated with adjuvant mFOLFIRINOX [5].”
BackgroundExosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?
Papadakos, S. P., Dedes, N., Pergaris, A., Gazouli, M., & Theocharis, S. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073620 · Cited by 24
“Nevertheless, the available therapeutic strategies have limited efficacy and the disease usually develops resistance to even the most active agents, such as gemcitabine [28,31].”
BackgroundTreatment for postoperative recurrence of pancreatic cancer: a narrative review
Okusaka, T. (2022) · Chinese Clinical Oncology · doi:10.21037/cco-21-87 · Cited by 23
Zarkavelis, G., Amylidi, A.-L., Verbaanderd, C., Cherny, N. I., Metaxas, Y., de Vries, E. G. E., Zygoura, P., Amaral, T. M. S., Jordan, K., Strijbos, M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100604 · Cited by 28
“1 score of A/4 and 5 in the adjuvant and advanced settings of pancreatic cancer respectively.(10,11) In addition, capecitabine combined with gemcitabine improved OS over gemcitabine monotherapy when used as adjuvant therapy in pancreatic cancer according to the ESPAC-4 trial, with an ESMO-MCBS version 1.”
MethodZhou, S., Song, B., Li, C., Tang, W., Zhang, X., Jin, X., Xu, X., Wang, Q., Zheng, H., & Fu, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-27824-9 · Cited by 23
The Gut Microbiome and Pancreatic Cancer Development and Treatment
Attebury, H., & Daley, D. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000647 · Cited by 30
“4 versus 35 months in the gemcitabine group.(31) As a result of these trials, FOLFIRINOX or modified FOLFORINOX remains first-line therapy for the treatment of resectable and advanced PDA.”
Functional and Clinical Proteomic Exploration of Pancreatic Cancer
Huang, P., Gao, W., Fu, C., & Tian, R. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100575 · Cited by 26
CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy
Liu, Z., Shi, Y.-H., Xu, Q., Zhao, G.-Y., Zhu, Y., Li, F.-X., Ma, M., Ye, J., Huang, X., Wang, X., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216640 · Cited by 23
Asano, D., Nara, S., Kishi, Y., Esaki, M., Hiraoka, N., Tanabe, M., & Shimada, K. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07390-z · Cited by 23
Kaissis, G. A., & Braren, R. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.05.04 · Cited by 26
Kaissis, G. A., Jungmann, F., Ziegelmayer, S., Lohöfer, F. K., Harder, F. N., Schlitter, A. M., Muckenhuber, A., Steiger, K., Schirren, R., Frieß, H., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051250 · Cited by 25
“Even in the setting of tumor resection and adjuvant chemotherapy [3], patients often develop therapy-resistant tumor recurrence or metachronous metastatic disease.”
BackgroundBai, Z., Xu, F., Feng, X., Wu, Y. S., Lv, J., Shi, Y., & Pei, H. (2022) · Bioengineered · doi:10.1080/21655979.2021.2019873 · Cited by 21
“The median overall survival of patients in FOLFIRINOX and Gemcitabine groups was only 54.4 and 35.0 months, respectively [4].”
InfluentialRetractedZhang, Q., Luo, Y., Liang, B., Suo, D., Lyu, S., Wang, Y., & Zhao, X. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.212831 · Cited by 21
Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma
Mas, L., Cros, J. F., Svrcek, M., Laethem, J. V., Emile, J., Rebours, V., Nicolle, R., & Bachet, J. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102108 · Cited by 23
Self-citationPrecision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment
Vitorakis, N., Gargalionis, A. N., Papavassiliou, K. A., Adamopoulos, C., & Papavassiliou, A. G. (2024) · Cancers · doi:10.3390/cancers16162876 · Cited by 29
“Currently, some of the adjuvant treatment modalities include revised FOLFIRINOX, gemcitabine combined with cisplatin, gemcitabine with nab-paclitaxel, and single-agent gemcitabine or fluorouracil [63].”
BackgroundBai, X., Li, X., Chen, Y., Qiao, G., Zhang, Q., Ma, T., Gao, S., Zhang, M., Shen, Y., Wu, J., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.09.009 · Cited by 29
Markus, M., Abendroth, A., Noureddine, R., Paul, A., Breitenbuecher, S., Virchow, I., Schmid, K. W., Markus, P. M., Schumacher, B. M., Wiesweg, M., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03361-0 · Cited by 22
Saha, A., Zhao, S., Chen, Z., Georgiou, G., Stone, E. M., Kidane, D., & DiGiovanni, J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.016 · Cited by 24
Shi, H., Wei, Y., Cheng, S., Lu, Z., Zhang, K., Jiang, K., & Xu, Q. (2021) · Pancreatology · doi:10.1016/j.pan.2021.02.009 · Cited by 23
Hue, J. J., Bingmer, K. E., Sugumar, K., Ocuin, L. M., Rothermel, L. D., Winter, J. M., Ammori, J. B., & Hardacre, J. M. (2021) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-021-04949-8 · Cited by 22
“Single-agent chemotherapy is inferior to multi-agent regimens.(17,21,22,25) Past reports have similarly demonstrated that elderly patients receive any adjuvant chemotherapy in only 23%-50% of cases.”
BackgroundKamarajah, S. K., White, S. A., Naffouje, S. A., Salti, G. I., & Dahdaleh, F. S. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09823-0 · Cited by 22
MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer
Singh, H. M., Leber, M. F., Bossow, S., Engeland, C. E., Dessila, J., Grossardt, C., Zaoui, K., Bell, J. C., Jäger, D., Kalle, C. V., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.04.015 · Cited by 27
Öman, M., Wettergren, Y., Odin, E., Westermark, S., Naredi, P. L. J., Hemmingsson, O., & Taflin, H. A. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04318-x · Cited by 22
Oba, A., Wu, Y. H. A., Lieu, C. H., Meguid, C. L., Colborn, K. L., Beaty, L. E., Al-Musawi, M. H., Davis, S. L., Leal, A. D., Purcell, T., et al. (2021) · British journal of surgery · doi:10.1093/bjs/znab092 · Cited by 22
Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
Velasco, R., Alemany, M., Villagrán‐García, M., & Argyriou, A. A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070669 · Cited by 25
“Oxaliplatin (OXA) is widely used for the treatment of gastrointestinal cancers including colorectal (CRC), gastric, and pancreatic cancer, both in the adjuvant and metastatic setting [1,2].”
BackgroundPancreatic Masses in Children and Young Adults: Multimodality Review with Pathologic Correlation
Qiu, L., Trout, A. T., Ayyala, R. S., Szabo, S., Nathan, J. D., Geller, J. I., & Dillman, J. R. (2021) · Radiographics · doi:10.1148/rg.2021210008 · Cited by 22
Resection of Recurrent Pancreatic Cancer: Who Can Benefit?
Nienhüser, H., Büchler, M. W., & Schneider, M. A. (2021) · Visceral Medicine · doi:10.1159/000519754 · Cited by 24
Treatment and survival of patients with pancreatic ductal adenocarcinoma: 15-year national cohort
Nymo, L. S., Myklebust, T. Å., Hamre, H. M., Møller, B., & Lassen, K. (2022) · BJS Open · doi:10.1093/bjsopen/zrac004 · Cited by 22
Prassas, D., Safi, S. A., Stylianidi, M. C., Telan, L., Krieg, S., Roderburg, C., Esposito, I., Luedde, T., Knoefel, W. T., & Krieg, A. H. (2022) · Cancers · doi:10.3390/cancers14071834 · Cited by 22
Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care
Casolino, R., Corbo, V., Beer, P. A., Hwang, C., Paiella, S., Silvestri, V., Ottini, L., & Biankin, A. V. (2022) · Cancers · doi:10.3390/cancers14133239 · Cited by 24
Javed, A. A., van Oosten, A. F., Habib, J. R., Hasanain, A., Kinny‐Köster, B., Gemenetzis, G., Groot, V. P., Ding, D., Cameron, J. L., Lafaro, K. J., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005710 · Cited by 22
“Postoperative trCTCs, present 7 (18) 9 (21) 11 (55) 0.”
Elrakaybi, A., Ruess, D. A., Lübbert, M., Quante, M., & Becker, H. (2022) · Cancers · doi:10.3390/cancers14235926 · Cited by 24
“Depending on the performance status, combination therapies of 5-fluoruracil, irinotecan and oxaliplatin (FOLFIRINOX) or of gemcitabine and nab-paclitaxel or a monotherapy with gemcitabine are the current first-line standard chemotherapy protocols for PDAC patients in the palliative setting [5,6].”
BackgroundZhou, B., Mei, Y.-Z., Wang, J., Xia, J.-L., Jiang, X., Ju, S.-Y., & Ding, Y. (2023) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223231155119 · Cited by 25
“pylori infection was determined by serological test such as enzyme-linked immunosorbent assay (ELISA), westerning blotting (WB), or another reliable methods; (3) the diagnostic method of pancreatic cancer should be stated; (4) the study presented the odds ratio (OR), hazard ratio (HR), and risk ratio (RR) with 95% con…”
MethodLan, X., Robin, G., Kasnik, J., Wong, G., & Abdel-Rahman, O. M. (2023) · Cancers · doi:10.3390/cancers15041331 · Cited by 27
“Current systemic therapy options in the metastatic setting include modified FOLFIRINOX or gemcitabine +/− nab-paclitaxel [15,18,19].”
BackgroundBrooks, G. A., Tomaino, M., Ramkumar, N., Wang, Q., Kapadia, N. S., O’Malley, A. J., Wong, S. L., Loehrer, A. P., & Tosteson, A. N. A. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad102 · Cited by 29
Chen, Q., Guo, H., Jiang, H., Hu, Z., Yang, X., Yuan, Z., Gao, Y., Zhang, G., & Bai, Y. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01661-1 · Cited by 29
“Next, chemotherapy evidently weakens the patients, lowering their tolerance to aggressive therapy and prolonging survival rather than effectively curing them [5].”
BackgroundStosic, K., Senar, O. A., Tarfouss, J., Bouchart, C., Navez, J., Laethem, J. V., & Arsenijevic, T. (2023) · Cells · doi:10.3390/cells13010003 · Cited by 24
“Nowadays two main chemotherapeutic regimens have proven their efficacy in PDAC management: FOLFIRINOX and nab-paclitaxel/gemcitabine in metastatic disease and the former in an adjuvant setting after surgery [6,7].”
BackgroundStereotactic body radiotherapy for pancreatic cancer – A systematic review of prospective data
Shouman, M. A., Fuchs, F., Walter, F., Corradini, S., Westphalen, C. B., Vornhülz, M., Beyer, G., Andrade, D., Belka, C., Niyazi, M., et al. (2024) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2024.100738 · Cited by 44
“Surgery followed by adjuvant chemotherapy is the standard of care in RPC and achieve a 5-year OS > 40 % [16,22,106].”
BackgroundRasmussen, L. S., Vittrup, B., Ladekarl, M. B., Pfeiffer, P., Yilmaz, M., Poulsen, L. Ø., Østerlind, K., Hansen, C. P., Mortensen, M. B., Mortensen, F. V., et al. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1581374 · Cited by 22
Intracellular Ion Channels in Pancreas Cancer
Patel, S. H., Edwards, M. J., & Ahmad, S. A. (2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000193 · Cited by 23
Barnes, C. A., Aldakkak, M., Christians, K. K., Clarke, C. N., Dua, K. S., George, B., Ritch, P. S., Kamgar, M., Hall, W. A., Kulkarni, N. M., et al. (2020) · Surgery · doi:10.1016/j.surg.2020.04.031 · Cited by 22
Al‐Batran, S., Hofheinz, R., Reichart, A., Pauligk, C., Schönherr, C., Schlag, R., Siegler, G. M., Dörfel, S., Koenigsmann, M., Zahn, M., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33336 · Cited by 22
“Due to the successful establishment of modified FOLFIRINOX as a standard of care in the adjuvant treatment in pancreatic cancer, the role of first-line nab-paclitaxel and gemcitabine even becomes more important.(15) However, the What's new?”
BackgroundCurrent controversies and advances in the management of pancreatic adenocarcinoma
Zeeshan, M. S., & Ramzan, Z. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i6.472 · Cited by 24
van Oosten, A. F., Daamen, L. A., Groot, V. P., Biesma, N. C., Habib, J. R., van Goor, I. W. J. M., Kinny‐Köster, B., Burkhart, R. A., Wolfgang, C. L., van Santvoort, H. C., et al. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.04.009 · Cited by 28
Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells
Yoon, J. H., Yoon, H., Kang, H. J., Yoo, H., Choi, M. J., Chung, J.-Y., Seo, M., Kim, M., Lim, S. O., Kim, Y. J., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200777 · Cited by 21
“3,4 This limited ef fi - cacy can be attributed to the unique tumor microenvironment (TME) prevalent in PDAC, characterized by a strong desmoplastic reaction.”
BackgroundCao, R., Feng, Z., Mo, J., Wu, J., Li, J., Li, W., Wang, Z., Ma, Q., Wu, Z., & Zhou, C. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111381 · Cited by 22
Fang, Z., Wu, Z. K., Yu, C., Xie, Q., Zeng, L., & Chen, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02262-5 · Cited by 24
“Chemoradiotherapy and immunotherapy have limited efficacy in patients with unresectable PDAC [5].”
Daniel, N., Farinella, R., Belluomini, F., Fajkić, A., Rizzato, C., Souček, P., Campa, D., & Hughes, D. J. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.03.002 · Cited by 25
Chen, G., Li, T., Duan, R. X., Liang, W., Li, B., Xie, X., Yang, L., Shuai, X., & Meng, X. (2025) · ACS Nano · doi:10.1021/acsnano.5c01280 · Cited by 21
Molecular radionuclide imaging of pancreatic neoplasms
Panda, A., Garg, I., Johnson, G. B., Truty, M. J., Halfdanarson, T. R., & Goenka, A. H. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30081-0 · Cited by 26
Promising new treatments for pancreatic cancer in the era of targeted and immune therapies.
Elaileh, A., Saharia, A., Potter, L. M., Baio, F. E., Ghafel, A. N., Abdelrahim, M., & Heyne, K. (2019) · Europe PMC (PubMed Central) · Cited by 24
Pancreatic Cancer: A Time to Change
Ferrone, C. R., & Ryan, D. P. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003910 · Cited by 21
“And (6) it delivers the most active chemotherapy regimen to a group of patients in whom the clear majority have occult systemic metastases.”
BackgroundO’Connor, D., Brown, M., Eatock, M. M., Turkington, R. C., & Prue, G. (2021) · BMC Cancer · doi:10.1186/s12885-020-07733-0 · Cited by 21
Poly( ADP ‐ribose) polymerase inhibition in pancreatic cancer
Singh, H. M., Bailey, P. J., Hübschmann, D., Berger, A. K., Neoptolemos, J. P., Jäger, D., Siveke, J. T., & Springfeld, C. (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22932 · Cited by 23
Moik, F., Makatsariya, A. D., & Ay, C. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2020.12.016 · Cited by 21
Irreversible electroporation of locally advanced pancreatic cancer
Kwon, W., Thomas, A. S., & Kluger, M. D. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.004 · Cited by 22
A Pretreatment Prognostic Score to Stratify Survival in Pancreatic Cancer
Hank, T. P., Hinz, U., Reiner, T., Malleo, G., König, A., Maggino, L., Marchegiani, G., Kaiser, J., Paiella, S., Binco, A., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000004845 · Cited by 25
Park, N., Lee, S. H., You, M. S., Kim, J. S., Huh, G., Chun, J. W., Cho, I. R., Paik, W. H., Ryu, J. K., & Kim, Y. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01755-z · Cited by 21
State-of-the-art surgery for pancreatic cancer
Nießen, A., & Hackert, T. (2021) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-021-02362-y · Cited by 21
Shoucair, S., Habib, J. R., Pu, N., Kinny‐Köster, B., van Oosten, A. F., Javed, A. A., Lafaro, K. J., He, J. P., Wolfgang, C. L., & Yu, J. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11081-z · Cited by 21
Kirkegård, J., Bojesen, A. B., Nielsen, M. F., & Mortensen, F. V. (2022) · Cancer Epidemiology · doi:10.1016/j.canep.2022.102230 · Cited by 22
Quiñonero, F., Mesas, C., Muñoz‐Gámez, J. A., Jiménez‐Luna, C., Perazzoli, G., Prados, J. C., Melguizo, C., & Ortíz, R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113669 · Cited by 24
Land, F. R. V. ‘., Aziz, M. H., Michiels, N., Mieog, J. S. D., Bonsing, B. A., Luelmo, S. A. C., Homs, M. Y. V., Koerkamp, B. G., Papageorgiou, G., & van Eijck, C. H. J. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000005865 · Cited by 21
The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal Cancers
Lee, M. S., Kaseb, A. O., & Pant, S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3626 · Cited by 24
van Eijck, C. W. F., Real, F. X., Malats, N., Vadgama, D., van den Bosch, T. P. P., Doukas, M., van Eijck, C. H. J., & Mustafa, D. A. M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101557 · Cited by 28
Zhou, Q., Andersson, R. E., Hu, D., Bauden, M. P., Sasor, A., Bygott, T., Pawłowski, K., Plá, I., Marko‐Varga, G., & Ansari, D. (2019) · Translational research · doi:10.1016/j.trsl.2019.06.003 · Cited by 22
Hospice utilization among Medicare beneficiaries dying from pancreatic cancer
Paredes, A. Z., Hyer, J. M., Tsilimigras, D. I., Mehta, R., Sahara, K., White, S., Dillhoff, M. E., Ejaz, A. M., Cloyd, J. M., & Pawlik, T. M. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25623 · Cited by 21
Mesmar, F., Dai, B., Ibrahim, A. A., Hases, L., Jafferali, M. H., Augustine, J. J., DiLorenzo, S., Kang, Y., Zhao, Y., Wang, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2581 · Cited by 21
Kubo, H., Murakami, T., Matsuyama, R., Yabushita, Y., Tsuchiya, N., Sawada, Y., Homma, Y., Kumamoto, T., & Endo, I. (2019) · World Journal of Surgery · doi:10.1007/s00268-019-05159-9 · Cited by 21
Abbas, A. I. A., Falvello, V. B., Zenati, M. S., Mani, A., Hogg, M. E., Zeh, H. J., Singhi, A. D., Bahary, N., & Zureikat, A. H. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25808 · Cited by 21
Farge, D., Bournet, B., Conroy, T., Vicaut, É., Rak, J. W., Zogoulous, G., Barkun, J., Ouaïssi, M., Buscail, L., & Frère, C. (2020) · Cancers · doi:10.3390/cancers12030618 · Cited by 24
Self-citationImmunotherapy for pancreatic cancer: chasing the light at the end of the tunnel
Brouwer, T. P., Vahrmeijer, A. L., & de Miranda, N. F. C. C. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00587-z · Cited by 23
Zhou, Y., Liao, S., You, J., & Wu, H. (2021) · Updates in Surgery · doi:10.1007/s13304-021-01089-1 · Cited by 21
“Although adjuvant chemotherapy has demonstrated clear benefits in PDAC patients who underwent upfront resection [45], there lacks solid evidence to support the use of adjuvant chemotherapy for patients treated with preoperative therapy and surgery.”
BackgroundOrganoid‐based precision medicine in pancreatic cancer
Beutel, A. K., Ekizce, M., Ettrich, T. J., Seufferlein, T. T. W., Lindenmayer, J., Gout, J., & Kleger, A. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12701 · Cited by 28
Ramesh, R. P. G., Yasmin, H., Ponnachan, P., al-Ramadi, B. K., Kishore, U., & Joseph, A. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573522 · Cited by 22
Advances in the Management of Pancreatic Cancer: Current Strategies and Emerging Therapies
Peshin, S., Takrori, E., Kodali, N. A., Bashir, F., & Singal, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157055 · Cited by 26
“This regimen significantly improved mOS to 54.4 months compared to 35 months with gemcitabine monotherapy (HR, 0.64; 95% CI, 0.48–0.86; p < 0.001), establishing it as the current standard for fit patients [32,39].”
InfluentialHue, J. J., Katayama, E., Sugumar, K., Winter, J. M., Ammori, J. B., Rothermel, L. D., Hardacre, J. M., & Ocuin, L. M. (2020) · Surgery · doi:10.1016/j.surg.2020.11.026 · Cited by 20
Primary Pancreatic Signet Ring Cell Carcinoma: A Case Report and Review of the Literature
Campbell, D. J., Isch, E. L., Kozak, G. M., & Yeo, C. J. (2021) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2020.0013 · Cited by 20
“Specifically, in 2018, the Canadian Cancer Trails Group and the Unicancer GI-PRODIGE Group conducted a multicenter international randomized phase III trial comparing gemcitabine monotherapy with FOLFIRINOX as an adjuvant treatment.(35) The FOLFIRINOX group showed improved median OS”
Takeda, T., Sasaki, T., Mie, T., Furukawa, T., Yamada, Y., Kasuga, A., Matsuyama, M., Ozaka, M., & Sasahira, N. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa247 · Cited by 20
Is Improved Survival in Early-Stage Pancreatic Cancer Worth the Extra Cost at High-Volume Centers?
Perry, L. M., Bateni, S. B., Bold, R. J., & Hoch, J. S. (2021) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2021.02.014 · Cited by 20
Narayanan, S., AlMasri, S. S., Zenati, M. S., Nassour, I., Chopra, A., Rieser, C. J., Smith, K., Oyefusi, V., Daum, T., Bahary, N., et al. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26510 · Cited by 21
Ji, W., Sun, X., Gao, Y., Lu, M., Zhu, L., Wang, D., Hu, C., Chen, J., & Cao, P. (2022) · Molecules · doi:10.3390/molecules27092747 · Cited by 20
“Although a large number of clinical trials with different combinations of chemotherapy have been conducted to identify reasonable regimens that can prolong the survival time of patients, the side effects are numerous, with only modest improvements in survival [5,6].”
BackgroundMARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer
Zeng, Y., Yin, L., Zhou, J., Zeng, R., Xiao, Y., Black, A. R., Hu, T., Singh, P. K., Yin, F., Batra, S. K., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02399-3 · Cited by 23
“However, approximately 69 to 75% of patients who receive adjuvant treatment relapse within 2 years [11, 12].”
BackgroundNaffouje, S. A., Kamarajah, S. K., Denbo, J. W., Salti, G. I., & Dahdaleh, F. S. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12347-w · Cited by 20
Halloran, C. M., Neoptolemos, J. P., Jackson, R., Platt, K., Psarelli, E., Reddy, S., Gomez, D., O'Reilly, D. A., Smith, A. M., Pausch, T. M., et al. (2022) · Annals of Surgery Open · doi:10.1097/as9.0000000000000198 · Cited by 23
Manderlier, M., Navez, J., Hein, M., Engelholm, J.-L., Closset, J., Bali, M. A., Gestel, D. V., Moretti, L., Laethem, J. V., & Bouchart, C. (2022) · Cancers · doi:10.3390/cancers14235730 · Cited by 22
Ca 125 is an independent prognostic marker in resected pancreatic cancer of the head of the pancreas
Napoli, N., Kauffmann, E. F., Ginesini, M., Lami, L., Lombardo, C., Vistoli, F., Campani, D., & Boggi, U. (2023) · Updates in Surgery · doi:10.1007/s13304-023-01587-4 · Cited by 20
Eijkelenkamp, H., Grimbergen, G., Daamen, L. A., Heerkens, H. D., van de Ven, S., Mook, S., Meijer, G. J., Molenaar, I. Q., van Santvoort, H. C., Paulson, E. S., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1040673 · Cited by 22
“Local recurrence events are very common in pancreatic cancer when patients are managed with surgery fi rst (31, 32).”
BackgroundDaamen, L. A., Molenaar, I. Q., & Groot, V. P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237485 · Cited by 28
“Moreover, muti-drug regimens such as FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin) or gemcitabine combined with nab-paclitaxel have augmented the available treatment options and strategies [4,5].”
Background
Metadata
- Authors
- Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., Lecomte, T., Assenat, E., Faroux, R., Ychou, M., Volet, J., Sauvanet, A., Breysacher, G., Di Fiore, F., Cripps, C., Kavan, P., Texereau, P., Bouhier-Leporrier, K., Khemissa-Akouz, F., Legoux, J.-L., Juzyna, B., Gourgou, S., O’Callaghan, C. J., Jouffroy-Zeller, C., Rat, P., Malka, D., Castan, F., & Bachet, J.-B.
- Affiliations
- Hôpital Beaujon (FR)
- From the Institut de Cancérologie de Lorraine and Université de Lorraine (T.C.) and Centre Hospitalier Universitaire (L.C.), Nancy, Hôpital Beaujon and University Paris VII, Clichy (P.H., A.S.), Hôpital Huriez, Lille (M.H.), Centre Paul Strauss, Strasbourg (M.B.A.), Institut Paoli-Calmettes, Marseille (J.-L.R.), Centre Antoine-Lacassagne, Nice (E.F.), Hôpital Jean-Mermoz, Lyon (P.A.), Hôpital Trousseau, Tours (T.L.), Centre Hospitalier Universitaire de Saint-Eloi (E.A.) and Institut du Cancer de...
- Université de Montpellier (FR)
- Université Paris-Saclay (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-12-20
- Volume
- 379
- Issue
- 25
- Pages
- 2395-2406
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903623792
- Cited by
- 2,874
- References
- 22
- Citations by year
- 2026: 219 · 2025: 316 · 2024: 337 · 2023: 457 · 2022: 449 · 2021: 512 · 2020: 376 · 2019: 202 · 2018: 1
- FWCI
- 102.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Canadian Cancer Society (Program Grant #704970)
- Institut National du Cancer (Clinical Research Hospital Program grant (PHRC11-0)
- 7 Days in May
- French National League against Cancer
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- FOLFIRINOX, gemcitabine, adjuvant chemotherapy, pancreatic ductal adenocarcinoma, resected pancreatic cancer, disease-free survival, overall survival, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, adverse events, treatment safety, secondary malignancies, metastatic pancreatic cancer, combination chemotherapy
- MeSH terms
- Irinotecan, Oxaliplatin, Gemcitabine, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Deoxycytidine, Drug Combinations, Female, Fluorouracil, Humans, Male, Middle Aged, Organometallic Compounds, Pancreatic Neoplasms, Prospective Studies, Proportional Hazards Models, Chemotherapy, Adjuvant, Lung Diseases, Interstitial, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.